Neogen Chemicals Limited held its Q1 FY27 Earnings Conference Call on July 27, 2026, at 4:00 PM IST. The transcript was filed with the exchanges on August 1, 2026.

Financial Performance Highlights (Consolidated, YoY Comparison)

  • Revenue from Operations: ₹250 crore, up 34% from ₹187 crore in Q1 FY26
  • EBITDA: ₹48.2 crore, up 53% from ₹31.5 crore in Q1 FY26
  • EBITDA Margin: 19.3%, expanded by 260 basis points
  • Profit After Tax (PAT): ₹17.1 crore, up 67% YoY
  • PAT Margin: 6.8%
  • Gross Profit: ₹117 crore, up 37% YoY
  • Depreciation: ₹8.2 crore, up 42% due to recent CAPEX additions
  • Finance Cost: ₹20.8 crore, up 64% due to higher debt drawdown for Neogen Ionics CAPEX and increased working capital intensity

Segment-wise Revenue Performance

  • Organic Chemicals: ₹194 crore, up 18% YoY
  • Inorganic Chemicals: ₹57 crore, up 158% YoY
  • Battery Chemicals (Neogen Ionics): ₹19 crore (vs ₹5 crore in Q1 FY26)

Operational and Strategic Updates

1. Dahej Replacement Plant and Insurance Recovery

  • Reconstruction of the replacement facility at Dahej is almost complete
  • Trial runs are underway with commercial production set to commence in Q2 FY27
  • Cumulative insurance recoveries to date: ₹164 crore (includes on-account claims and salvage realization)
  • Net claim receivable (consolidated): ₹186 crore as of date
  • Company continues engagement with insurers for final settlement and additional recoveries under other policies (e.g., loss of profit)

2. Fundraise via QIP

  • Board approved raising ₹600 crore through Qualified Institutional Placement (QIP)
  • Purpose: To support long-term capital requirements, deleverage balance sheet, and prepare for growth opportunities in battery materials and organo-lithium space
  • Subject to shareholder and regulatory approvals

3. Battery Chemicals and Neogen Ionics Performance

  • Neogen Ionics delivered ₹19 crore revenue in Q1 FY27 (50% of FY26 full-year revenue)
  • Execution on schedule for battery material facility:
  • Electrolyte commissioning targeted for H1 FY27
  • Lithium electrolyte salts commissioning targeted for H2 FY27
  • Mechanical assembly for electrolyte plant complete; trial runs initiated
  • Product validation with leading domestic cell manufacturer in progress
  • Secured provisional approvals from 4 international customers for lithium electrolyte salts
  • Completed final site audits from all 4 electrolyte manufacturers
  • Commercial supplies to commence post final plant trial approvals
  • Strategic partner Morita remains committed to USD 20 million equity contribution to JV (expected during Q2-Q3 FY27)

4. Market Opportunity and Government Support

  • Domestic battery demand projected to surge from 33 GWh to 92 GWh by 2027 and over 200 GWh by 2032 (Ministry of Heavy Industries report)
  • 63 GWh currently under development in India; 30 GWh expected commissioning in 2026 alone
  • Government support through PLI ACC battery manufacturing scheme and proposed PLI for battery components
  • 10 GWh ACC PLI re-bidding tranche allocated

Guidance and Outlook

  • Revised Standalone Revenue Guidance for FY27: ₹950-1,050 crore (increased from previous ₹875-950 crore)
  • Battery Chemicals Revenue Guidance for FY27: ₹300 crore (₹200 crore from salts, ₹100 crore from electrolyte)
  • Battery Chemicals Capacity Utilization Target by FY29: 70-80% for salts, 30-50% for electrolyte
  • Expected Revenue Potential from Current CAPEX: ₹2,400-2,900 crore by FY29 (full utilization)
  • Base Business Growth Expectation for FY28: 10-15% growth (₹1,100-1,200 crore revenue)
  • EBITDA Margin Guidance:
  • Base business: 18% ±1.5% for FY27; 18-20% for FY28
  • Battery business: Targeting 20% ROCE at full utilization

Capital Expenditure and Financing

  • Total battery chemicals CAPEX: ₹1,800 crore
  • CAPEX spent to date: ₹1,300 crore
  • Remaining CAPEX: ₹500 crore (to be completed by FY27 end)
  • Financing: Debt drawdown, Morita equity contribution (USD 20 million), and ~₹40-50 crore equity from Neogen
  • Peak debt (before QIP): ~₹1,800 crore net
  • Expected debt post QIP: ₹1,000-1,500 crore

Working Capital Management

  • Base business target working capital cycle: 140-160 days currently, improving to 110-120 days long-term
  • Battery business target working capital cycle: 90 days
  • Expected significant improvement in working capital efficiency by FY28-FY29

Other Business Updates

  • Organo-lithium business hit peak capacity utilization in Q1 FY27
  • Planning incremental capacity expansion for organo-lithium (<₹10-15 crore CAPEX)
  • CSM (Contract Synthesis and Manufacturing) business remains engaged with customers; clearer outlook expected in FY28
  • Published first integrated annual report for FY26 including BRSR and Reasonable Assurance Report

Management Participants

  • Dr. Harin Kanani (Managing Director)
  • Mr. Gopikrishnan Sarathy (Chief Financial Officer)
  • Mr. Anurag Surana (Non-Executive Chairman)
  • Mr. Nishid Solanki (CDR India, Moderator)